Here are the 10-K annual reports from Klotho Neurosciences, Inc. (KLTO) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow KLTO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KLTO filings page.
Greenland Mines Ltd (GRML), formerly Klotho Neurosciences, described its medicine-development business and reported completing the acquisition of Greenland Mines Corp. in March 2026, adding critical- and precious-minerals development and mining.
Its medicine programs include licensed generic drugs and biosimilar biologics, plus a patented Klotho gene-therapy platform. Lead candidates KLTO-101 for Alzheimer’s disease and KLTO-202 for ALS are preclinical; Greenland Mines states it has not submitted an IND application for any gene therapy.
The company says additional funding from equity and/or debt securities is needed to execute development plans and continue operations. Without it, substantial doubt exists about its ability to continue as a going concern for twelve months from the financial statements’ date. Management found disclosure controls and internal controls over financial reporting ineffective as of December 31, 2025, citing inadequate accounting resources, lack of segregation of duties and a need for a stronger control environment. After additional analyses and procedures, management said the 2025 financial statements were fairly stated in all material respects under GAAP.